SCHEMBL11045073

SCHEMBL11045073

COC(=O)c1ccccc1NC(=O)c1ccc(OC)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 1/20 0.77
TSHR P16473 3/20 0.76
KDM4E B2RXH2 3/20 0.76
HSD17B10 Q99714 2/20 0.76
CYP1A2 P05177 1/20 0.74
CYP2D6 P10635 1/20 0.74
CYP2C19 P33261 1/20 0.74
ELANE P08246 1/20 0.71
PRTN3 P24158 1/20 0.71
APOBEC3A P31941 1/20 0.68
APOBEC3G Q9HC16 1/20 0.68
HDAC3 O15379 1/20 0.67
HDAC4 P56524 1/20 0.67
HDAC1 Q13547 1/20 0.67
HDAC7 Q8WUI4 1/20 0.67
HDAC2 Q92769 1/20 0.67
HDAC10 Q969S8 1/20 0.67
HDAC11 Q96DB2 1/20 0.67
HDAC8 Q9BY41 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314038 0.88 F10 (0.77) F10TSHRKDM4EHSD17B10HDAC3
SCHEMBL14338416 0.88 F10 (0.77) F10HDAC3HDAC4HDAC1HDAC7
SCHEMBL11665959 0.87 TSHR (0.77) TSHRKDM4EHSD17B10CYP1A2CYP2D6
SCHEMBL6349025 0.87 ELANE (0.70) F10TSHRKDM4EHSD17B10CYP1A2
SCHEMBL4203434 0.86 TSHR (0.76) TSHRKDM4EHSD17B10CYP1A2CYP2D6
SCHEMBL9339256 0.86 TSHR (0.76) TSHRKDM4EHSD17B10CYP1A2CYP2D6
SCHEMBL7315643 0.86 HDAC1 (0.64) F10TSHRKDM4EHSD17B10CYP1A2
SCHEMBL28439421 0.85 F10 (0.72) F10TSHRKDM4EHSD17B10HDAC3
SCHEMBL14855681 0.85 F10 (0.72) F10HDAC3HDAC4HDAC1HDAC7
SCHEMBL9002518 0.85 F10 (0.72) F10KDM4EHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8552065-B2 Biarylamide derivative and compositions containing the derivative as an active ingredient CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) 2013-10-08 US disclosed
US-8552065-B2 Biarylamide derivative and compositions containing the derivative as an active ingredient CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) 2013-10-08 US disclosed
US-20120289595-A1 NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) 2012-11-15 US disclosed
US-20120289595-A1 NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) 2012-11-15 US disclosed
US-4454324-A Process for production of encainide MEAD JOHNSON & COMPANY (US) 1984-06-12 US disclosed
US-4394507-A Process for production of encainide MEAD JOHNSON & COMPANY (US) 1983-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289595-A1 NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT TYR, MITF, MC1R F10 3827/4885TSHR 3003/4885KDM4E 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.